2 results
Approved WMOWill not start
Primary: efficacy of GSK1605786 at week 12 following twice daily administration at 500 mg in patients with active ulcerative colitis. Secondary: safety and tolerability, time course of the efficacy of GSK1605786 continued for up to 16 weeks, anti-…
Divergent Low Level Laser Therapy as novel treatment for oral mucositis in pediatric cancer patients
Primary Objective: - To assess the effect of divergent LLLT on the number of days of mucositis > grade 1Secondary Objective(s): - To assess the effect of divergent LLLT on the severity of mucositis - To assess the effect of divergent LLLT on…